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Edited by Beat ImhofAbstract The G6b gene, located in the human Major Histocom-
patibility Complex, encodes a receptor of the immunoglobulin
(Ig) superfamily. In this study, we show using a variety of tech-
niques that the extracellular domain of the G6b protein, contain-
ing a single Ig-like domain, binds to heparin with high aﬃnity. In
an ELISA assay, this binding was displaceable with soluble hep-
arin with an IC50 value of approximately 0.5 lg/ml. Other sul-
fated glycans showed weaker or no competition. The observed
interaction between G6b and heparin is strongly salt dependent
suggesting a mainly electrostatic interaction. Heparin might
modulate the interaction of G6b with its as yet unidentiﬁed pro-
tein ligand.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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glycan; MHC1. Introduction
The G6b gene, located in the class III region of the Major
Histocompatibility Complex, encodes a novel cell surface
receptor of the immunoglobulin (Ig) superfamily [1]. This
superfamily contains a large group of cell surface receptors in-
volved in cellular recognition and signal transduction [2]. The
G6b gene undergoes alternative splicing giving rise to multiple
membrane bound and soluble isoforms. The two major mem-
brane bound isoforms (G6b-A and G6b-B) contain a single Ig-
like domain and transmembrane segment, but diﬀer in their
cytoplasmic tails. G6b-B contains two immunoreceptor tyro-
sine-based inhibitory motifs (ITIMs) in its cytoplasmic tail
which are not found in the G6b-A isoform. G6b-B binds the
protein tyrosine phosphatases SHP-1 and SHP-2 after per-
vanadate-induced phosphorylation of these ITIMs, classifyingAbbreviations: BSA, bovine serum albumin; ELISA, enzyme-linked
immunosorbent assay; FGF, ﬁbroblast growth factor; Ig, immuno-
globulin; PBS, phosphate buﬀered saline; SDS–PAGE, sodium dode-
cylsulfate–polyacrylamide gel electrophoresis
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doi:10.1016/j.febslet.2005.03.032this isoform as a new member of the family of inhibitory
receptors [1].
A crucial part in understanding the in vivo function of the
G6b protein is the identiﬁcation of its extracellular ligand. Pro-
tein ligands for Ig superfamily members are often, but not
exclusively, other Ig superfamily members [2]. Interactions be-
tween Ig superfamily members and their respective ligands are
usually low aﬃnity which makes the identiﬁcation of those li-
gands experimentally challenging [3,4]. However, certain Ig
superfamily members have been reported to bind to non-pro-
tein molecules such as the siglec family of receptors which bind
sialic acid [5]. In addition, other cell surface proteins, such as
members of the ﬁbroblast growth factor receptors and selectins
[6], as well as a number of cytokines including interleukin-2 [7],
interleukin-6 [8] and interleukin-12 [9], have been shown to
bind to heparin and heparan sulfate, highly sulfated, nega-
tively charged, glycosaminoglycans that are widely distributed
in the extracellular matrix and on the cell surface. The binding
of proteins to heparin is thought to play an essential biological
role. For example, in the case of the basic ﬁbroblast growth
factor receptor heparin/heparan sulfate is essential for this pro-
tein to bind to its ligand [10,11]. In the case of cytokines it has
been suggested that heparin-like glycans retain the secreted
cytokine close to their sites of secretion [9] thus giving rise to
localized high concentrations of the cytokine.
In this study, we show using a variety of techniques that the
extracellular domain of the G6b protein binds to heparin and
provide evidence that this interaction is mainly electrostatic.
Although a protein ligand for the extracellular part of G6b
has not been identiﬁed, the binding of heparin might play an
essential role in the biological function of G6b.2. Materials and methods
2.1. Cloning of expression constructs
The constructs encoding full length N-terminally tagged G6b-A and
G6b-B are described elsewhere [1]. As negative controls full length hu-
man CD86 (NM_175862) and human SIRPalpha (BC033092) were
cloned under the control of the CD33 leader peptide and containing
an N-terminal T7 epitope tag similar to the cloning of N-terminally
tagged G6b-A and G6b-B [1]. To create a soluble protein the cDNA
encoding the extracellular domain of G6b including the endogenous
hydrophobic signal peptide (amino acids 1–142) was ampliﬁed by
PCR using a full length clone as template. The forward primer created
a HindIII site (underlined) TTATAAGCTTACCATGGCTGT-
GTTTCTGC and the reverse primer introduced aNotI site (underlined)
ATCCGCGGCCGCCTGGGGATACACGGACCC. This PCR frag-
ment was cloned into the HindIII–NotI sites of the pIgplus vector
(Novagen) creating a construct encoding the leader peptide andblished by Elsevier B.V. All rights reserved.
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(G6b-Fc). The extracellular domains of the human G6f protein and hu-
man CD152 were cloned as Fc fusions in a similar way.
2.2. Heparin agarose binding assay
Proteins were transiently expressed in Cos-7 cells using the DEAE
dextran method in 6 well plates as described before [12]. For pull down
assays with the full length cellular proteins the transfected Cos-7 cells
were washed with PBS and lysed in lysis buﬀer (10 mM Tris/HCl pH
7.5, 1% NP-40, 150 mM NaCl, 0.02% sodium azide) supplemented
with protease inhibitor cocktail (Sigma) and 1 mg/ml BSA (0.6 ml/
well). An aliquot of the lysate was mixed with approximately 10 ll
of heparin-agarose gel (Sigma) in 200 ll of lysis buﬀer containing
1 mg/ml BSA in the absence or presence of 1 mg/ml soluble heparin.
The mixture was rotated at room temperature for 1 h and the beads
were spun down and washed twice with lysis buﬀer. Proteins were
eluted from the beads by addition of Laemmli SDS–PAGE sample
buﬀer [13] containing 5% b-mercaptoethanol. Samples were directly
analysed by Western blot immunostaining and proteins were detected
with the anti-T7 tag mAb (Novagen) as described before [1]. Pull down
assays with the soluble Fc-fusion proteins were performed by mixing
100 ll of culture supernatant containing the soluble recombinant pro-
tein with 10 ll heparin agarose gel in 100 ll lysis buﬀer supplemented
with 0.1 mg/ml BSA. The mixture was incubated for 1 h at room tem-
perature. Beads were spun down and washed twice with lysis buﬀer.
Proteins were eluted from the beads with Laemmli SDS–PAGE sample
buﬀer and analysed by Western blot immunostaining. The Fc-fusion
proteins were detected with a goat anti-human IgG (c-chain speciﬁc)
peroxidase-conjugated antibody (Sigma).Fig. 1. Western blot analysis of heparin-agarose binding assay. A
heparin-agarose binding assay was performed on full length T7-tagged
solubilised proteins (left panels) and soluble Fc fusion proteins (right
panels). The starting material for both experiments is shown in the
upper panels, the eluates from heparin-agarose in the middle panels,
and the eluates from heparin-agarose when the experiment was
performed in the presence of soluble heparin (1 mg/ml) in the lower
panels. The Western blots are representative of three identical
experiments.2.3. FACS analysis of transfected HEK293 cells
HEK293 cells were grown in DMEM medium supplemented with
10% foetal calf serum and penicillin/streptomycin and were transfected
in 6 well plates (2.5 · 105 cells/well) with Eﬀectene (Qiagen) according
to the manufacturers protocol. The constructs encoding full length
G6b-A and G6f (N-terminally tagged with the T7 epitope) have been
described before [1,14]. Cells were harvested three days after transfec-
tion by resuspending them in fresh medium. For the detection of hep-
arin binding, 2.5 · 105 cells per incubation were spun down, washed in
PBS and incubated for 45 min at room temperature in PBS containing
0.2 mg/ml BSA and 50 lg/ml heparin-biotin. Cells were spun down,
washed with PBS/BSA and incubated with streptavidin-PE-Cy5 (BD
Pharmingen) for 45 min at room temperature. Cells were spun down
and ﬁxed in PBS/1% formaldehyde. To detect expression of the T7-
tagged proteins on the cell surface, cells were also stained with the
T7 tag mAb using anti-mouse IgG-FITC as secondary antibody.
FACS analysis was done on a Beckman Coulter EPICS-XL machine.
2.4. Heparin ELISA
The Fc-fusion proteins were expressed in Cos-7 cells for three days
and then puriﬁed batchwise from culture supernatants using protein
A-Sepharose (Sigma). Typically, to 30 ml of culture supernatant
50 ll of protein A-Sepharose gel was added and the mixture was incu-
bated for 4 h at 4 C under rotation. The protein A-Sepharose gel was
washed twice with cold PBS and the Fc-fusion proteins were eluted
with 0.1 M glycine pH 3.2. The eluates were neutralized with Tris to
pH  7.5 and BSA was added to a ﬁnal concentration of 0.1 mg/ml.
Proteins were stored in aliquots at 20 C.
A 96 well ﬂat bottom ELISA plate (Greiner) was coated overnight
with 5 lg/ml avidin in PBS (100 ll/well) at 4 C. The rest of the exper-
iment was done at room temperature. The plate was washed with PBS
and wells were incubated with heparin-biotin (Sigma) in PBS (20 lg/
ml, 100 ll/well) for 2 h. After washing with PBS the wells were blocked
with 2% milk powder in PBS for 1 h. The plate was washed with PBS/
0.05% Tween-20 and wells were incubated for 2 h with the Fc fusion
proteins (approximately 12 ng/well) in 80 ll PBS/0.2 mg/ml BSA in
the absence or presence of various glycan/sugars which were purchased
from Sigma. In the case of the measurement of the inﬂuence of NaCl
on the binding of G6b-Fc to heparin, 10 mM Tris/HCl (pH 7.5) was
used instead of PBS with NaCl added at the indicated concentrations.
The wells were washed three times with PBS/Tween and incubated for
30 min with a 1:1000 dilution of goat anti-human (Fc speciﬁc) alkaline
phosphatase conjugate (Sigma) in PBS/2% milk powder. Wells were
washed three times with PBS/Tween and subsequently three times withPBS. Alkaline phosphatase was detected by adding 100 ll of p-nitro-
phenyl phosphate substrate (Sigma) to the wells. Reactions were
stopped typically after 10–15 min with EDTA and the OD405 was
measured using a Fusione a plate reader (Packard Bioscience). Wells
not incubated with a Fc fusion protein were used as blanks.3. Results
3.1. Heparin agarose binding assay
To establish a direct interaction between heparin and G6b a
heparin-agarose pull down experiment was performed. Both
solubilised T7-tagged full length G6b-A and G6b-B interacted
with heparin-agarose whereas other T7-tagged proteins bound
to a much lesser extent (CD86) or not at all (SIRPalpha) under
identical experimental conditions (Fig. 1, left panel). A fusion
protein containing only the extracellular part of G6b fused to
the Fc tail of human IgG1 (G6b-Fc) also interacted with hep-
arin-agarose whereas other Fc fusions (G6f and CD152) or the
Fc domain itself did not (Fig. 1, right panel). These interac-
tions could be eﬃciently blocked by the addition of soluble
heparin (1 mg/ml) indicating that the extracellular part of
G6b recognizes heparin on the beads (Fig. 1), an interaction
that might be biologically relevant.
3.2. Binding of heparin to HEK293 cells
HEK293 cells, which do not express endogenous G6b, were
transfected with either G6b-A or empty vector (pcDNA3). Fig.
2 shows that cells transfected with G6b can bind heparin
whereas cells transfected with the empty vector do not bind
heparin. Staining with the T7 mAb showed that the cells were
eﬃciently transfected with G6b (Fig. 2, right panel). Further-
more, HEK293 cells transfected with full length G6f and
Fig. 2. FACS analysis of binding of heparin-biotin to G6b expressed
on the surface of HEK293 cells. Cells were transfected with empty
vector (pcDNA3) (closed line) or T7-tagged full length G6b-A (hashed
line) and after 3 days were stained with heparin-biotin (left panel) or
the T7 mAb (right panel). Unstained and untransfected cells are shown
in grey.
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iment shows that the extracellular domain of G6b expressed on
a cell surface is able to bind heparin.
3.3. Heparin ELISA
To investigate whether other glycans were able to compete
with the binding of G6b to heparin, an ELISA based approach
was used. As shown in Fig. 3A, the G6b-Fc fusion protein
showed binding to immobilized heparin in this assay whereas
G6f-Fc, CD152-Fc and Fc alone did not bind. These experi-
ments were carried out in PBS, at physiological salt (NaCl)
concentration (0.15 M). Subsequently, this assay was used to
determine whether various glycans could inhibit the binding
of G6b-Fc to immobilized heparin. Soluble heparin was the
most eﬃcient competitor to binding of G6b-Fc to immobilized
heparin with an IC50 value of the order of 0.5 lg/ml (Fig. 3B).
Certain sulfated glycans like fucoidan, heparan sulfate and
chondroitin sulfate B were also able to compete although not
as eﬃciently as heparin yielding much higher IC50 values of
approximately 3, 100 and 10 lg/ml, respectively. Sialic acid,
hyaluronic acid, chondroitin sulfate C and sodium sulfateFig. 3. ELISA of G6b-Fc binding to immobilized heparin. (A) Binding of va
glycans/sugars on the binding of the G6b-Fc protein to immobilized heparin.
sugar/glycans as well as Na2SO4 at the indicated concentrations. Results ar
absence of any potential inhibitor. Results are averaged over six independendid not compete with the binding of G6b-Fc to immobilized
heparin. We also observed that the addition of EDTA at a
concentration of 5 mM did not aﬀect the binding of G6b-Fc
to immobilized heparin making the involvement of a divalent
cation in the interaction unlikely (data not shown). Further-
more, the heparin disaccharide I-S (Sigma) did not inhibit
binding of G6b-Fc to heparin at concentrations as high as
100 lg/ml (data not shown) which suggests that heparin binds
to G6b through more than two sugar residues.
To investigate whether the interaction between heparin and
G6b was governed by electrostatic interactions, we examined
the eﬀect of NaCl concentration on the binding of G6b to hep-
arin in the ELISA. Although the G6b-Fc fusion protein clearly
binds to immobilized heparin with high aﬃnity at physiologi-
cal salt concentration as shown by the data in Fig. 3, about 3-
fold more binding is observed in the presence of 100 mM NaCl
(Fig. 4). As the binding of G6b-Fc to immobilized heparin is
strongly salt dependent this suggests a strong electrostatic con-
tribution to the binding of G6b to heparin.4. Discussion
In this paper, we show that the extracellular domain of the
cell surface molecule G6b binds heparin. In an ELISA-based
approach, it was found that soluble heparin competed for
the binding of G6b to immobilized heparin with an IC50 value
of 0.5 lg/ml. This value is of the same order of magnitude as
those obtained for the binding of heparin to interleukin-12
(0.1 lg/ml) [9], FGF-2 (0.15 lg/ml) and anti-thrombin III
(1 lg/ml) [7]. This indicates an aﬃnity of G6b for heparin com-
parable to these high-aﬃnity heparin-binding proteins. Other
sulfated glycans were able to compete for the binding of G6b
to heparin although with much lower aﬃnities. This suggests
a speciﬁcity of G6b for heparin. However, highly sulfated
fucoidan (based on fucose residues) is a much more eﬃcient
competitor than heparan sulfate which is structurally more re-
lated to heparin than fucoidan. For that reason it is possible
that it is the level of negative charge/sulfation on the glycan
that determines the observed high aﬃnity of G6b for heparinrious Fc-fusion proteins to immobilized heparin. (B) Eﬀect of various
The ELISA experiment was performed in the presence of the indicated
e expressed as the percentage of signal observed with G6b-Fc in the
tly performed experiments.
Fig. 4. Salt dependence of the binding of the G6b-Fc protein to
immobilized heparin. The binding of G6b-Fc to heparin was
performed at the indicated NaCl concentrations.
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strong inﬂuence of the NaCl concentration on this interaction
lends further support to the notion that the interaction is
mainly electrostatic.
Stretches of positively charged residues in the primary se-
quence have been identiﬁed as heparin binding motifs, for
example the C-terminal proximal clusters of 4–5 basic resi-
dues that give rise to the heparin binding properties of
IFN-c [15] and interleukin-8 [16]. However, basic residues
that are far apart in the primary sequence can be close in
the folded protein. Some heparin binding proteins are known
to contain large positively charged surfaces which mediate
high aﬃnity binding of heparin [17]. In this respect it should
be noted that the extracellular domain of G6b is particularly
enriched in positively charged residues, especially arginines
(12 arginines in a 125 amino acid domain) which are known
to mediate strong binding to heparin [18]. The Ig fold is well
characterised (see [19] for a detailed description of the Ig
fold) and it can be hypothesized that in the G6b protein a
number of basic residues (R43, K54, K58, R60, R61,
K109, R111 and R117) will be located in that part of its
Ig-like domain made up of the GFCC b-sheet strands. These
residues might form a positively charged surface able to bind
heparin. In addition, a number of basic residues are likely to
be located in that part of the Ig-like domain of G6b made
up of the ABED b-sheet strands (R26, R30, R83, R85,
R92 and R93) and these could also be involved in heparin
binding.
The physiological relevance of the observed interaction be-
tween G6b and heparin remains to be established. The protein
ligand of G6b is unknown hampering further investigations. It
is a possibility that heparin binding modulates the interaction
between G6b and its as yet unidentiﬁed protein ligand as is ob-
served with the interaction of FGF with various FGF recep-
tors [11]. Alternatively, G6b might mediate the adhesion of
cells to heparin in the extracellular matrix or present on the
surface of other cells. Once a protein ligand for G6b is identi-
ﬁed, a more detailed study of the functional importance of the
observed interaction between heparin and G6b can be under-
taken.Acknowledgements: This work was funded by the Medical Research
Council, United Kingdom. S.A.B.N. holds a MRC studentship.References
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